Genetic Risk Factors for Adverse Reactions

Inherited variation in genes that govern how drugs are absorbed, metabolised, transported, and recognised influences who is most likely to suffer an adverse reaction. This topic surveys the categories of genetic risk factor, from pharmacokinetic enzyme variants that change drug exposure to immune-related variants, and how they combine with non-genetic factors to determine individual susceptibility.

Definition

Genetic risk factors for adverse reactions are heritable DNA variants that increase an individual's probability of experiencing a harmful, unintended response to a medicine by altering drug disposition, target sensitivity, or immune recognition.

Scope

The entry organises genetic contributors to adverse drug reactions by mechanism: drug-metabolising enzymes, transporters, drug targets, and immune-recognition genes. It explains why most reactions are multifactorial, how effect sizes differ between common pharmacokinetic variants and high-impact HLA alleles, and how genetic risk is identified through candidate-gene and genome-wide approaches. It is reference-educational and not a basis for testing or treatment decisions.

Core questions

• What categories of gene variant contribute to adverse drug reaction risk?
• How do pharmacokinetic variants differ from immune-mediated risk factors in effect size?
• Why are most adverse reactions multifactorial rather than determined by a single gene?
• How are genetic risk factors discovered and validated?

Key concepts

• Drug-metabolising enzyme variants (e.g., CYP, TPMT, DPYD)
• Transporter variants affecting drug disposition
• Drug-target (pharmacodynamic) variants
• Immune-recognition variants such as HLA alleles
• Candidate-gene versus genome-wide discovery
• Gene-environment and polygenic contributions

Mechanisms

Genetic risk factors act at distinct steps of the drug's journey. Variants in metabolising enzymes change the rate at which a drug is cleared or activated, so poor metabolisers may accumulate toxic concentrations while ultrarapid metabolisers may overproduce active or reactive species. Transporter variants alter tissue distribution and elimination. Variants in drug targets change pharmacodynamic sensitivity, and immune-recognition variants such as HLA alleles determine whether a drug provokes a T-cell response. Because these factors interact with dose, age, organ function, and co-medication, risk is usually multifactorial rather than monogenic.

Clinical relevance

Understanding genetic risk factors helps explain why patients given identical regimens differ in their likelihood of harm, and underpins how pharmacogenomic evidence is generated and weighed. This topic is for educational appraisal of those mechanisms and the evidence behind them; it does not provide individualized risk estimates, testing recommendations, or treatment guidance.

Epidemiology

Adverse drug reactions are a frequent cause of healthcare harm, with a large prospective study attributing about 6.5% of hospital admissions to them. The contribution of any single genetic factor varies: common metabolic variants are widespread but typically modest in effect, whereas high-impact alleles for specific severe reactions are individually rare. The frequency of risk variants also differs substantially across ancestral populations.

Evidence & guidelines

Evidence comes from candidate-gene studies, genome-wide association studies, and prospective cohorts quantifying overall reaction burden. Consortia including the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group synthesise validated gene-drug associations into guidelines, demonstrating how genetic risk findings progress toward practice while remaining outside the individualized scope of this reference.

History

The concept of inherited differences in drug response dates to mid-twentieth-century observations of enzyme deficiencies such as slow acetylation and thiopurine intolerance. The genomic era broadened the search from single candidate genes to genome-wide scans, uncovering both common pharmacokinetic variants and rarer high-risk immune alleles, and motivating consortium guidelines that catalogue clinically relevant gene-drug associations.

Debates

Should testing be pre-emptive (panel-based) or reactive (single-gene at prescribing)?

Pre-emptive panel genotyping promises efficiency across a patient's lifetime of prescriptions, but raises questions of cost, interpretation, and clinical utility for variants of modest effect, while reactive testing targets known high-impact pairs.

Key figures

• Richard Weinshilboum
• Howard McLeod
• Grant Wilkinson
• Munir Pirmohamed

Seminal works

• wang-2011
• wilkinson-2005
• pirmohamed-2004

Frequently asked questions

Is a single gene usually responsible for an adverse drug reaction?

Rarely. A few severe reactions are dominated by one high-impact allele, but most reactions arise from a combination of genetic variants and non-genetic factors such as dose, organ function, age, and other medicines.

How are new genetic risk factors discovered?

Through candidate-gene studies that test biologically plausible variants and genome-wide association studies that scan the whole genome in patients with and without the reaction, with findings then replicated in independent samples.